Caribou Biosciences Inc (CRBU) - Total Liabilities
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has total liabilities worth $44.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Caribou Biosciences Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Caribou Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CRBU total asset value.
Caribou Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Caribou Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gatekeeper Systems Inc
V:GSI
|
Canada | CA$4.21 Million |
|
Prime Office A/S
CO:PRIMOF
|
Denmark | Dkr2.64 Billion |
|
Korea Information Certificate Authority Inc
KQ:053300
|
Korea | ₩170.54 Billion |
|
Impiana Hotels Bhd
KLSE:7243
|
Malaysia | RM195.30 Million |
|
Beijing Tongtech Co Ltd
SHE:300379
|
China | CN¥342.06 Million |
|
Corbus Pharmaceuticals Holding
NASDAQ:CRBP
|
USA | $24.75 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €3.44 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
USA | $48.06 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Caribou Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Caribou Biosciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caribou Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.19 Million | -11.88% |
| 2024-12-31 | $60.36 Million | -5.40% |
| 2023-12-31 | $63.81 Million | -12.46% |
| 2022-12-31 | $72.89 Million | +33.67% |
| 2021-12-31 | $54.53 Million | -8.33% |
| 2020-12-31 | $59.48 Million | +9.20% |
| 2019-12-31 | $54.47 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more